Novo Nordisk A S (NONOF) stock
NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$38.24−0.60 (-1.53%)
Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –
Novo Nordisk A S price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Novo Nordisk A S's price to sales ratio was 3.9× on Nov 3, 2026, against 4.9× a year earlier. Over the last 5 years it ranged from 3.4× to 20.7×, with a median of 13.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 3, 2026 | 3.9× | −1.1 |
| 2025 | Dec 31, 2025 | 5.0× | −6.9 |
| 2024 | Dec 31, 2024 | 11.9× | −5.8 |
| 2023 | Dec 29, 2023 | 17.7× | +2.3 |
| 2022 | Dec 30, 2022 | 15.4× | +1.8 |
| 2021 | Dec 31, 2021 | 13.6× | +5.3 |
| 2020 | Dec 31, 2020 | 8.4× | +0.0 |
| 2019 | Dec 31, 2019 | 8.4× | +1.7 |
| 2018 | Dec 31, 2018 | 6.7× | −0.9 |
| 2017 | Dec 29, 2017 | 7.5× | +1.5 |
| 2016 | Dec 30, 2016 | 6.0× | – |
See a number that looks wrong?